In summary, treatment of B-ALL mice with an MMP-9 inhibitor prolonged survival of mice with B-ALL, likely via reduction of the degradation of ECM proteins, without overt toxicity. This evidence concerns the gene MMP9 and precursor B-cell acute lymphoblastic leukemia.